Bayer, Onyx Offering Nexavar in Study - Forbes

Thu, 13 Sep 2007 00:16:51 +0000

Bayer, Onyx Offering Nexavar in Study
Forbes, NY -Aug 27, 2007
AP 08.27.07, 7:53 AM ET Bayer AG and Onyx Pharmaceuticals Inc. said Monday they are ending a late-stage trial of the cancer drug candidate Nexavar for liver ...

Bayer's Nexavar 'significantly' improved survival in Phase III ... - Forbes

Bayer's Nexavar'significantly' improved survival in Phase III ...
Forbes, NY -Aug 26, 2007
BERLIN (Thomson Financial) - Bayer AG and Onyx Pharmaceuticals Inc said an independent data monitoring committee found that cancer drug Nexavar...

Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority ... - Forbes

Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority ...
Forbes, NY -Aug 20, 2007
LEVE...

Onyx, Bayer Drug Gets Priority Review (AP via Yahoo! Finance)

Sun, 26 Aug 2007 00:17:07 +0000

Bayer AG and Onyx Pharmaceuticals Inc. said Monday the Food and Drug Administration gave priority review for the application of its drug Nexavar as a liver cancer treatment.

Bayer erhält von FDA "Priority Review"-Status für Nexavar (OnVista)
Wie bewerten Sie diese Seite' sehr gut 1 2 3 4 5 6 schlecht © 1998-2007 OnVista Group - Die OnVista Media GmbH übernimmt keine Haftung für die Richtigkeit der Angaben!

Staff Writer (BioWorld)
On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products.

Nexawar from Bayer, ONYX gets priority status from US FDA (New Ratings)
NEW YORK, August 20 (newratings.com) – Bayer AG and ONYX Pharmaceuticals, Inc ( ONXX.NAS ) Monday announced that the new drug application for their jointly developed Nexavar drug was granted priority review status by the Food and Drug Administration (FDA).

German shares flat afternoon as Bayer, VW help offset weak financials, ZEW index (FinanzNachrichten)
FRANKFURT (Thomson Financial) - German shares were largely flat in afternoon trade as German indices took a momentary break from today's roller-coaster ride....

Nexavar Granted FDA Priority Review for Treatment of Liver Cancer

Sat, 25 Aug 2007 23:17:24 +0000

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the supplemental New Drug Application (sNDA) for Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), ...

Nexavar Granted FDA Priority Review For Treatment Of Liver Cancer
“This Priority Review underscores the potential of Nexavar to be a significant advance in the treatment of liver cancer,” said Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. ...

Onyx Expects Early 2008 Launch For Nexavar In Liver Cancer
Firm expects more off-label use of Nexavar in liver cancer in second half of 2007.

Bayer And Onyx Submit Supplemental New Drug Application For ...
(Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the US Food and Drug Administration (FDA) for the treatment of patients with hepatocellular ...

Nexavar prolongs survival among Liver cancer patients
The findings of a clinical trial presented by doctors at the American Society of Clinical Oncology meeting in Chicago on Monday provided hope to the deadly liver cancer patients as Nexavar, a drug developed by Onyx Pharmaceuticals Inc. ......

Bayer/Onyx: Nexavar approval in liver cancer on the horizon (Pharmaceutical Business Review)

Fri, 24 Aug 2007 00:25:25 +0000

Bayer and Onyxs Nexavar has been granted priority for hepatocellular carcinoma from the FDA and a final decision regarding its approval is now expected in the next few months. The drug has been shown to significantly extend overall survival in previously untreated patients, a population with a high unmet need, ensuring adoption as the standard of care for this patient group.

Nexavar Granted FDA Priority Review For Treatment Of Liver Cancer (Medical News Today)
Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. [click link for full ...

Nexavar Granted FDA Priority Review for Treatment of Liver Cancer (The San Francisco Examiner)
WAYNE, N.J. ( Map ) - Bayer HealthCare Pharmaceuticals (NYSE: BAY ) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. ...

Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority review (Sharewatch)
LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment of hepatocellular carcinoma, the most common form of liver cancer, has been accepted for review and granted priority review status by the US Food and Drug Administration.

Onyx, Bayer Drug Gets Priority Review (AP via Yahoo! Finance)
Bayer AG and ...

Nexavar: Nexavar

Wed, 22 Aug 2007 00:21:37 +0000

What is the most important information I should know about Nexavar' ... How can I get more information about insurance coverage for Nexavar' ...

Nexavar® : Onyx Pharmaceuticals
Changing the way cancer is treated ... Nexavar emerged from our collaboration with Bayer focused on identifying and ... Nexavar targets both the tumor cell and ...

FDA Approves New Treatment for Advanced Kidney Cancer
... Administration (FDA) today approved Nexavar (sorafenib tosylate), a new anti ... "The approval of Nexavar to treat advanced kidney cancer brings a much needed ...

NEXAVAR
NEXAVAR, a multikinase inhibitor targeting several serine/threonine and receptor ... Each red, round NEXAVAR film-coated tablet contains sorafenib tosylate ...

BRAND NAME Nexavar (Generic) (sorafenib)
... during the first 6 weeks of Nexavar therapy and thereafter monitored and treated, ... additional dose reduction is required, Nexavar may be reduced to a ......

Onyx shares up after Bayer announces Nexavar sales - Reuters

Tue, 21 Aug 2007 23:19:45 +0000

Onyx shares up after Bayer announces Nexavar sales
Reuters -Aug 7, 2007
DE: Quote, Profile, Research) reported a 161 rise in sales of their cancer drug Nexavar. Shares in Emeryville, California-based Onyx, which is scheduled to ...

TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... - Hemscott

TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ...
Hemscott, UK -Aug 20, 2007
LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment ...

Bayer: sales growth from Schering but future focus on Nexavar - Pharmaceutical Business Review

Bayer: sales growth from Schering but future focus on Nexavar
Pharmaceutical Business Revie...

Bayer, Onyx say FDA grants Nexavar liver cancer treatment priority ...

Tue, 21 Aug 2007 13:02:55 +0000

Forbes - LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment of hepatocellular carcinoma, the most common form of liver cancer, has been accepted for ...

Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Earthtimes - WAYNE, N.J., and EMERYVILLE, Calif., Aug. 20 -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets for the treatment of patients with ...

FDA gives Onyx liver cancer drug priority review
Reuters - BOSTON, Aug 20 (Reuters) - Onyx Pharmaceuticals Inc. (ONXX.O: Quote , Profile , Research ) and German partner Bayer AG (BAYG.DE: Quote , Profile , Research ) said on Monday that U.S. regulators agreed to review their drug Nexavar as a treatment for ...

Bayer HealthCare (BAY) and Onyx (ONXX) Announce FDA Grants Priority ...
StreetInsider.com - Bayer HealthCare (BAY) and Onyx (ONXX) Announce FDA Grants Priority Review for Nexavar in Treatment of Liver Cancer Dendreon (DNDN) Announces Positive Phase 1 Study of Neuvenge in Breast Cancer Indevus Phama (IDEV) Receives FDA 'Approvable Letter ...

Onyx, Bayer Drug Gets Priority Review
Forbes - Bayer AG and Onyx Pharmaceuticals Inc. said Monday the Food and Drug Administration gave priority review for the application of its drug Nexavar as a liver cancer treatment. The drug is already approved in more than 50 countries to treat advanced ... ...

Bayer: sales growth from Schering but future focus on Nexavar (Pharmaceutical Business Review)

Sun, 12 Aug 2007 00:15:22 +0000

Bayer Schering has reported robust second quarter sales, and an overall positive performance during the first half of the year, boosted by strong product lines such as Yasmin and Betaferon which were gained from the acquisition of Schering AG in 2006. However, the leading German pharmaceutical companys future focus relies heavily on the new oncology treatment Nexavar.

Onyx shares up after Bayer announces Nexavar sales (Reuters via Yahoo! Singapore News)
LOS ANGELES, Aug 7 - Shares in Onyx Pharmaceuticals Inc. rose as much a 9 percent after partner Bayer reported a 161 rise in sales of their cancer drug Nexavar.

Onyx Shines on Nexavar Sales (TheStreet.com)
Strong demand for the kidney-cancer drug sends shares up 8%.

Onyx Pharmaceuticals 2Q Loss Narrows (AP via Yahoo! Finance)
Onyx Pharmaceuticals Inc. said late Tuesday its second-quarter loss narrowed on lower operating expenses and a payment from Bayer for the liver cancer drug Nexavar.

Elderly parents of cancer sufferer forced to sell home to fund treatment (Daily Mail)
The elderly parents of a man denied a life-prolonging cancer drug said they will sell their home to help him survive. Ken and Irene Potts, both 78, said they would 'live in a tent' if the drug could help their sick son Ken ...

new to nexavar

Tue, 07 Aug 2007 00:15:49 +0000

Hello againMy mum has stage 4 RCCShe is on day 4 of nexavar treatment, very bad diarrhoea from day one and tongue quite sore and hot feet. She is also on her third course of zometa. Her breathing is very fast and shallow, which recently ...

Bayer And Onyx Submit Supplemental New Drug Application For ...
(Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the US Food and Drug Administration (FDA) for the treatment of with hepatocellular ...

WHERE CAN I FIND NEXAVAR AND WHAT DOES IT COST
The oncologist said my dad must get Nexavar but you cannot get it in South Africa. I was told that you can get it easily in London, America and Mexico.Can someone PLEASE help me and tell me where I can find it and more importantly, ...

Nexavar prolongs survival among Liver cancer patients
The findings of a clinical trial presented by doctors at the American Society of Clinical Oncology meeting in Chicago on Monday provided hope to the deadly liver cancer patients as Nexavar, a drug developed by Onyx Pharmaceuticals Inc. ...

Bayer: Phase 3 Study: Nexavar Significantly Extends Overall ...
The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo. Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those ......

The Top 20 Cancer Therapy Brands Are Forecast to Experience 144 Different Events between 2007 and 2016 (Business Wire via Yahoo! Finance)

Sun, 29 Jul 2007 09:15:25 +0000

DUBLIN, Ireland----Research and Markets has announced the addition of Commercial Insight: Top 20 Cancer Therapy Brands - Sales of Targeted Therapies Overtake Cytotoxics in 2006 to their offering.

Learn about the Top 20 Cancer Therapy Brands - Sales of Targeted Therapies Overtake Cytotoxics in 2006 (Business Wire via Yahoo! Finance)
LYON, France----Reportlinker.com announces that a new market research report related to the worldwide oncology industry is now available to its catalogue.

Overview of Hepatocellular Carcinoma Provided by New Report (Business Wire via Yahoo! Finance)
DUBLIN, Ireland----Research and Markets has announced the addition of "Stakeholder Opinions: Hepatocellular Carcinoma - Opportune Indication For Novel Therapies" to their offering.

Slight Setback for ImClone (The Motley Fool)
ImClone announces a failed cancer study.

Cancer sufferer Ken starts course of drug treatment (Blyth and Wansbeck Today)
A BLYTH caretaker battling cancer has just started a course of tablets costing thousands of pounds per month after a fundraising drive led by family, friends, and complete strangers. (10/07/2007 13:37:09)...

Treatment for Advanced Renal Cell Carcinoma (RCC) Kidney Cancer, Patient Resources, Reimbursement Information: ...

Sun, 29 Jul 2007 06:15:46 +0000

Information about Nexavar and its use in the treatment of the kidney cancer known as advanced renal cell carcinoma (RCC). From Bayer Pharmaceuticals and Onyx Pharmaceuticals.

Patient Information Sheet - Sorafenib (marketed as Nexavar)
Patient information sheet for the prescription Sorafenib, marketed as Nexavar, from the U.S. Food and Drug Administration.

Nexavar - Chemotherapy Drugs and Side Effects
Describes the side effects and precuations to be taken while undergoing treatment with the chemothrapy drug Nexavar (Sorafenib).

Nexavar (Sorafenib) drug description - prescription drugs and medications at RxList
Offers pharmacology, indications, dosage, side effects, and patient information for the prescription drug used to treat advanced renal cell carcinoma.

Nexavar Information from Drugs.com
Information about the medication Nexavar (Sorafenib), used to treat a type of kidney cancer, including its side effects and contraindications....

Decision is too late for cancer sufferer - The Northern Echo

Sun, 29 Jul 2007 00:15:39 +0000

Decision is too late for cancer sufferer
The Northern Echo, UK -Jul 27, 2007
Ironically, Mrs Devonport's consultant decided to put her on Nexavar, a similar drug to Sutent which is also licensed but can only be purchased privately. ...
Kidney cancer drug decision hailed as 'major breakthrough'The Northern Echo
all 2 news articles

Bayer and Onyx submit supplemental NDA for Nexavar - News-Medical.net

Bayer and Onyx submit supplemental NDA for Nexavar
News-Medical.net, Australia -Jun 28, 2007
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has ...

Bayer and Onyx Submit Supplemental New Drug Application for ... - MedIn...

The Seven Hottest Stocks of the Second Quarter (Morningstar.com via Yahoo! Finance)

Sat, 28 Jul 2007 21:16:46 +0000
Despite their popularity, these stocks are trading for less than they're worth.

Familiar TRAIL Followed To New Cancer Therapy (Medical News Today)
A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. [click link for full article]

Before the Call: Gauging Genentech (The Motley Fool)
Quarter, schmorter. What's the big picture look like'

Scientists Follow Familiar 'TRAIL' To New Cancer Therapy (Science Daily)
A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor death receptor ligand against a variety of human cancers.

Dow Jones Picks the Top 5 Hedge Fund Trades Thus Far (PR Newswire via Yahoo! Finance)
Despite the problems the industry faces from fractures in the sub-prime mortgage sector, some hedge funds continue to rake in big profits through astute stock trading, according to Hedge Fund Trades, the weekly e-newsletter from Dow Jones....

Bayer: Phase 3 Study: Nexavar Significantly Extends Overall ...

Sat, 28 Jul 2007 18:17:15 +0000
The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo. Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those ...

Nexavar prolongs survival among Liver cancer patients
The findings of a clinical trial presented by doctors at the American Society of Clinical Oncology meeting in Chicago on Monday provided hope to the deadly liver cancer patients as Nexavar, a drug developed by Onyx Pharmaceuticals Inc. ...

Bayer And Onyx Submit Supplemental New Drug Application For ...
(Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the US Food and Drug Administration (FDA) for the treatment of patients with hepatocellular ...

Nexavar (sorafenib) and HCC
Data presented today at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) has shown that Nexavar (sorafenib) tablets significantly extended overall survival (OS) in patients with advanced hepatocellular ...

Liver Cancer Patients May Have 44% Higher Survival Rate By Nexavar
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc. today announced that Nexavar tablets significantly extended overall survival in patients with hepatocellular carcinoma , or primary liver ... via Huliq.com....

Kidney medication buys time for patients with liver tumors

Sat, 28 Jul 2007 16:50:59 +0000
Jackson Clarion-Ledger - That's why doctors are excited about Nexavar, a pill first approved for kidney cancer in 2005, says Josep Llovet of Mount Sinai School of Medicine in New York, lead author of the new study. In an international study of 602 patients with hepatocellular ...

Chemo and Surgery May Help Colon Cancer
Newsday - Those results occurred in patients with advanced liver cancer treated with the drug sorafenib, or Nexavar, which is marketed by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc. to treat advanced kidney cancer. The companies are expected to ...

Bayer seeks liver cancer OK for Nexavar
United Press International - WAYNE, N.J., June 27 (UPI) -- Bayer and Onyx Wednesday filed a supplemental new drug application with the U.S. Food and Drug Administration for Nexavar for treating liver cancer. Nexavar, which is currently approved for treating advanced kidney ...

Fury over £84,000 NHS trip to Japan
This is North East - Ray Devonport, from Newton Aycliffe, County Durham, whose wife, Kathleen, 63, has been able to get access to an advanced kidney cancer drug - called Nexavar - only through the generosity of an anonymous benefactor, who paid her 9,000 drug bill, also ...

Stakeholder Opinions: Hepatocellular Carcinoma - Opportune indication ...
Pharmaceutical Business Review - The majority consist of targeted therapies, with Bayer-Schering/Onyx's Nexavar, Genentech/Roche's Avastin and OSI/Genentech/Roche's Tarceva considered to have the highest clinical and commercial potential. Why you should buy this report Evaluate ... ...

Nexavar